Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting neddylation inhibits intravascular survival and extravasation of cancer cells to prevent lung-cancer metastasis

(2019) Yanyu Jiang et al.   CELL BIOLOGY AND TOXICOLOGY

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

(2018) Ronan T. Swords et al.   BLOOD

Protein neddylation and its alterations in human cancers for targeted therapy

(2018) Lisha Zhou et al.   CELLULAR SIGNALLING

The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma

(2018) Wenjuan Zhang et al.   CELL PROLIFERATION

Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival

(2017) Ahmedin Jemal et al.   JNCI-Journal of the National Cancer Institute

Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival

(2017) Ahmedin Jemal et al.   JNCI-Journal of the National Cancer Institute

Non–Small Cell Lung Cancer

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma

(2017) Shuai Tong et al.   Scientific Reports

Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage

(2016) Weihua Zhou et al.   CLINICAL CANCER RESEARCH

Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4–CHOP–DR5 Axis in Human Esophageal Cancer Cells

(2016) Ping Chen et al.   CLINICAL CANCER RESEARCH

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

(2016) Shailender Bhatia et al.   INVESTIGATIONAL NEW DRUGS

Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells

(2016) Huiyin Lan et al.   Scientific Reports

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

(2015) Ronan T. Swords et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells

(2015) Yanchun Wang et al.   CANCER BIOLOGY & THERAPY

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

(2015) J. J. Shah et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

(2015) J. Sarantopoulos et al.   CLINICAL CANCER RESEARCH

Refining the treatment of NSCLC according to histological and molecular subtypes

(2015) Anish Thomas et al.   Nature Reviews Clinical Oncology

Protein neddylation: beyond cullin–RING ligases

(2015) Radoslav I. Enchev et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Suppression of glioblastoma by targeting the overactivated protein neddylation pathway

(2015) Wei Hua et al.   NEURO-ONCOLOGY

Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target

(2015) Qiang Gao et al.   Oncotarget

Induction of p21-Dependent Senescence by an NAE Inhibitor, MLN4924, as a Mechanism of Growth Suppression

(2015) Lijun Jia et al.   NEOPLASIA

Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer

(2014) Lihui Li et al.   JNCI-Journal of the National Cancer Institute

Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells

(2014) G. Wei Xu et al.   PLoS One

Cullin-RING Ligases as Attractive Anti-cancer Targets

(2013) Yongchao Zhao et al.   CURRENT PHARMACEUTICAL DESIGN

Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

(2012) Michael A. Milhollen et al.   CANCER CELL

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of NEDD8-conjugation pathway by novel molecules: Potential approaches to anticancer therapy

(2012) Tomoaki Tanaka et al.   Molecular Oncology

A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924

(2012) Julia I. Toth et al.   Cell Reports

Identification of Genes Upregulated in ALK-Positive and EGFR/KRAS/ALK-Negative Lung Adenocarcinomas

(2011) H. Okayama et al.   CANCER RESEARCH

SCF E3 Ubiquitin Ligases as Anticancer Targets

(2011) L. Jia et al.   CURRENT CANCER DRUG TARGETS

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

(2010) R. T. Swords et al.   BLOOD

NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells

(2010) J. J. Lin et al.   CANCER RESEARCH

Therapy-Induced Senescence in Cancer

(2010) Jonathan A. Ewald et al.   JNCI-Journal of the National Cancer Institute

Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction

(2010) Jun Hou et al.   PLoS One

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

(2008) Kerby Shedden et al.   NATURE MEDICINE